Clinical trials: Finerenone
Chronic Kidney Disease, Proteinuria
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine.
- Trial name
- FIONA (NCT05196035)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 132 sites in United States, Argentina and 30 more
- Volunteers
- 219 people
- Sponsor
- Bayer
Heart Failure
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal…
- Trial name
- FINALITY-HF (NCT06033950)
- Testing
- Finerenone
- Where
- 176 sites in United States, Argentina and 12 more
- Volunteers
- 2,600 people
- Sponsor
- Colorado Prevention Center
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a long-term, progressive decrease in the kidneys' ability to work properly.
- Trial name
- FIGARO-BM (NCT05013008)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 115 sites in United States, Australia and 19 more
- Volunteers
- 951 people
- Sponsor
- Bayer
Chronic Heart Failure
A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea
This is an observational study in which data from people with chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40%. who will be receiving finerenone are studied.
- Trial name
- NCT07379840
- Testing
- finerenone (BAY94-8862)
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Bayer
Type2diabetes
Finerenone and Renal Oxidative Stress
The main goal of this mechanistic, prospective, double-blind, placebo controlled, randomized study is to demonstrate the effect of finerenone on the oxidative stress of renal vasculature.
- Trial name
- NCT06244758
- Testing
- Finerenone 20 MG Oral Tablet
- Where
- Germany
- Volunteers
- 91 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Clinical Pharmacology
Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862
Pharmacodynamics, pharmacokinetics, safety, and tolerability will be investigated in this single dose study. In 5 treatment groups, different dosages of BAY94-8862 will be given in healthy male subjects.
- Trial name
- NCT01473108
- Testing
- Finerenone (BAY 94-8862) PEG solution, Finerenone (BAY 94-8862) immediate release tablet, Eplerenone (Inspra®)
- Where
- Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Bayer
IgA Nephropathy (IgAN)
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
: IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy…
- Trial name
- NCT07056595
- Testing
- Finerenone
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Botkin Hospital
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
This is an observational study, in which data from people in the United States (US) with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied.
- Trial name
- FIRST-2 (NCT05703880)
- Testing
- Finerenone (Kerendia, BAY948862)
- Where
- 2 sites in United States
- Volunteers
- 15,948 people
- Sponsor
- Bayer
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
This is an observational study, in which data from people in Asia and in the United States with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied.
- Trial name
- FINEROD (NCT06278207)
- Testing
- Finerenone (BAY 94-8862)
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Acute Kidney Injury, Renal Insufficiency,Chronic
Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial
This study is testing whether finerenone, when compared to placebo, is a tolerable and safe intervention when administered in patients with acute kidney injury (AKI).
- Conditions
- Acute Kidney Injury, Renal Insufficiency,Chronic, Kidney Diseases
- Trial name
- FiPAKI (NCT07775482)
- Testing
- Finerenone (BAY94-8862 ) 10 mg
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Jean-Maxime Côté
T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
The purpose of this study is to evaluate whether adding dulaglutide to the combination therapy of Sodium-Glucose Co-Transporter 2 Inhibitors(SGLT2i) and finerenone can provide additional kidney protection and safety for Chinese…
- Trial name
- NCT07537088
- Testing
- Dulaglutide, SGLT2i, Finerenone
- Volunteers
- 468 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Primary Aldosteronism
Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism
To study the efficacy and safety of finerenone in patients with primary aldosteronism
- Trial name
- NCT05924620
- Testing
- finerenone
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing Medical University
Heart Failure
Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients
FINE-FOCUS study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of Finerenone versus placebo on myocardial fibrosis and cardiac structure/function as assessed by…
- Trial name
- FINE-FOCUS (NCT07583173)
- Testing
- Oral finerenone
- Where
- China
- Volunteers
- 104 people
- Sponsor
- China National Center for Cardiovascular Diseases
Heart Failure
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood…
- Trial name
- FINEARTS-HF (NCT04435626)
- Testing
- Finerenone (BAY94-8862)
- Where
- 661 sites in United States, Argentina and 35 more
- Volunteers
- 6,016 people
- Sponsor
- Bayer
Type 2 Diabetic Kidney Disease
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
This study employs a prospective, randomized, double-blind, parallel-controlled design, aiming to enroll adult participants with type 2 diabetic kidney disease (DKD) who meet the eligibility criteria.
- Trial name
- NCT07775846
- Testing
- empagliflozin, Finerenone, Mazdutide
- Where
- China
- Volunteers
- 820 people
- Sponsor
- Huijie Zhang
Heart Failure
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic…
- Trial name
- ARTS-HF (NCT01807221)
- Testing
- Finerenone (BAY94-8862), Inspra (eplerenone)
- Where
- 172 sites in United States, Australia and 23 more
- Volunteers
- 1,066 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus
Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.
The global prevalence of diabetes is increasing substantially. Around 40 % of patients with type 2 diabetes develop chronic kidney disease.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Cardiovascular Diseases
- Trial name
- FineCaRe (NCT07026539)
- Testing
- Finerenone (BAY 94-8862)
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- University of Aarhus
Heart Failure
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
- Trial name
- CONFIRMATION (NCT06024746)
- Testing
- Finerenone, Empagliflozin
- Where
- 140 sites in United States, Brazil and 6 more
- Volunteers
- 1,500 people
- Sponsor
- Colorado Prevention Center
Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
The goal of this clinical trial is to determine the feasibility of remote clinical trial conduct in patients with type 2 diabetes and elevated albuminuria.
- Conditions
- Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes
- Trial name
- Optimize@Home (NCT06094920)
- Testing
- Empagliflozin 10 MG, Finerenone, Withings BPM Connect
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- University Medical Center Groningen
Heart Failure With Reduced Ejection Fraction, Diabetes Mellitus
Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction
Finerenone is a new selective nonsteroidal mineral corticoid receptor antagonist (MRA), nowadays it's widely used in type 2 diabetes (T2DM) patients with chronic kidney disease (CKD), the newest trial shows finerenone improve the…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Diabetes Mellitus, Diabetic Nephropathies
- Trial name
- NCT05974566
- Volunteers
- 60 people
- Sponsor
- Chongqing Medical University